Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Journal: European urology open science
Published: May 20, 2026
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
Journal: Current opinion in urology
Published: October 09, 2025
Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2025
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.
Journal: ESMO open
Published: April 21, 2025
Primary sarcomas of the bladder and prostate: A genomic landscape study.
Journal: Pathology, research and practice
Published: December 20, 2024
Metastasis development in non-muscle-invasive bladder cancer.
Journal: Nature reviews. Urology
Published: October 18, 2024
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Journal: Urologic oncology
Published: September 30, 2024
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study.
Journal: Targeted oncology
Published: September 03, 2024
Last Updated: 09/26/2026